NEW YORK, February 14, 2017 /PRNewswire/ --
Stock-Callers.com is currently monitoring four Biotech equities to seehow they have fared at the close of the last trading session: Agenus Inc. (NASDAQ: AGEN), Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), Eleven Biotherapeutics Inc. (NASDAQ: EBIO), and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). These stocks are part of
At the close of trading on Monday, shares in Lexington, Massachusetts headquartered Agenus Inc. rose 0.73%, ending the day at $4.12. The stock recorded a trading volume of 567,008 shares. The Company's shares have advanced 1.23% in the last one month. The stock is trading above its 50-day moving average by 0.25%. Moreover, shares of Agenus, which focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 53.79.
On January 30th, 2017, Agenus announced that Jean-Marie Cuillerot, M.D. was appointed Chief Medical Officer. Dr. Cuillerot initially joined Agenus in 2016 as the Vice President and Global Head of Clinical Development. The Company stated that Dr. Cuillerot's past affiliations with Merck Serono and Bristol-Myers Squibb were accompanied by significant accomplishments that included the advancement of the PD-L1 antagonist antibody avelumab from first in man to regulatory filing in three and a half years. Access our complete research report on AGEN for free at:
Shares in Boston, Massachusetts-based Tokai Pharmaceuticals Inc. ended the day 0.11% lower at $0.94 with a total trading volume of 101,405 shares. The stock is trading below its 50-day moving average by 7.45%. Shares of the Company, which focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases, have an RSI of 45.50.
As per notes filed with the SEC on February 03rd, 2017, Tokai Pharmaceuticals entered into a stock purchase agreement with certain purchasers named therein on January 31st, 2017, under which the Purchasers agreed to purchase approximately $4,000,000 of Tokai common stock through the purchase of 3,603,601 shares of Tokai's common stock at a price of $1.11 per share. The Stock Purchase Agreement was entered into pursuant to the Company's previously disclosed commitment letter with Otic Pharma, Ltd, a private limited company organized under the laws of the State of Israel, and the Purchasers, under which the Purchasers agreed to invest up to $7,000,000 of new capital in Otic and/or Tokai prior to or upon the closing of the Transaction. The complimentary research report on TKAI can be downloaded at:
On Monday, shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. finished 2.78% lower at $2.10 with a total trading volume of 308,174 shares. The stock has advanced 9.95% on an YTD basis. The Company's shares are trading below their 50-day moving average by 2.12%. Additionally, shares of Eleven Biotherapeutics, which focuses on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics, have an RSI of 46.95. Register for free on Stock-Callers.com and get access to the latest PDF format report on EBIO at:
Rockville, Maryland-based Rexahn Pharmaceuticals Inc.'s shares recorded a trading volume of 22.62 million shares at the end of yesterday's session, which was above their three months average volume of 1.35 million shares. The stock edged 39.98% higher, closing the day at $0.28. The Company's shares have surged 78.13% in the last one month, 70.15% over the previous three months, and 100.85% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 74.08% and 29.16%, respectively. Additionally, shares of Rexahn Pharma, which discovers, develops, and commercializes treatments for cancer, have an RSI of 88.08.
On January 20th, 2017, Rexahn Pharmaceuticals announced an update on the safety and efficacy of RX-3117 in an ongoing Phase-IIa clinical trial in metastatic pancreatic cancer. The Company stated in the current study more than 20% of patients treated with RX-3117 exhibited progression free survival of greater than 5.6 months. An additional 20%, for a total of 40%, of the patients exhibited progression free survival of 2.5 months. RX-3117 was shown to be safe and well tolerated in this patient group. Patients in Stage-1 of the clinical trial are still being monitored for survival. An initial data read out from stage-2 of the trial is expected in late Q2 or early Q3 2017. Download your free research report on RNN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...View All